Gene Therapy Market PPT: Overview, Dynamics, Trends, Segmentation, Application and Forecast to 2032

Gene Therapy Market PPT: Overview, Dynamics, Trends, Segmentation, Application and Forecast to 2032

1. Global Gene Therapy Market Research and Forecast Report 2024-2032 Format: PDF+EXCEL © 2023 IMARC All Rights Reserved

2. About IMARC Group International Market Analysis Research and Consulting Group is a leading adviser on management strategy and market research worldwide. We partner with clients in all regions and industry verticals to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise. IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.

3. Report Highlight and Description According to the latest report by IMARC Group, titled  "Gene Therapy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032,"  the  global gene therapy market size reached US$ 5.1 Billion in 2023. Gene therapy refers to an advanced medical technique that involves modifying the genes inside the cells of the patient's body to treat or prevent the progression of the disease. It works by replacing a defective gene with a new, normal and healthy gene in a cell to cure the disease or improve the body's ability to fight it. It is also used to treat numerous chronic and genetic disorders in human beings that have no other cures. Nowadays, manufacturers are offering a wide variety of gene therapy products, including plasmid deoxyribonucleic acid (DNA), human gene-editing technology, patient-derived cellular gene therapy, viral vectors, and bacterial vectors, which is currently escalating their demand across the globe. Request for a PDF sample of this report: https://www.imarcgroup.com/gene-therapy-market/requestsample

4. Report Description Global Gene Therapy Market Trends : The rising prevalence of genetic and acquired diseases, such as cancer, diabetes, cardiovascular diseases (CVDs), cystic fibrosis, and acquired immunodeficiency syndrome (AIDS), represents the primary factor driving the market growth. Besides this, the expanding geriatric population that is more susceptible to developing such chronic health conditions has catalyzed the product demand. Additionally, there has been a significant increase in government support and funding for gene therapy research. Along with this, the growing awareness regarding the benefits of gene therapy and easy accessibility to healthcare facilities have accelerated the product adoption rate. Furthermore, several key players are engaging in research and development (R&D) activities and making heavy investments toward product innovations to gain a competitive edge. Moreover, the introduction of new gene therapy that provides a safer and non-addictive alternative to opioids in treating various chronic pain conditions, such as lower back pain and rare neuropathic pain disorders, has propelled the market growth. Other factors, including the increasing approvals of gene therapy products, favorable reimbursement policies, improving healthcare infrastructure, rising consumer healthcare expenditure, and technological advancements, are also providing a positive impact on the market growth. Looking forward, IMARC Group expects the market to reach US$ 16.8 Billion by 2032, growing at a CAGR of 13.9% during 2024-2032. View Report TOC, Figures and Tables : https://www.imarcgroup.com/gene-therapy-market

5. Report Segmentation Breakup by Gene Type: Antigen Cytokine Tumor Suppressor Suicide Gene Deficiency Growth Factors Receptors Others Breakup by Vector Type: Viral Vector Adenoviruses Lentiviruses Retroviruses Adeno-Associated Virus

6. Report Segmentation Herpes Simplex Virus Poxvirus Vaccinia Virus Others Non-Viral Techniques Naked and Plasmid Vectors Gene Gun Electroporation Lipofection Others Breakup by Delivery Method: In-Vivo Gene Therapy Ex-Vivo Gene Therapy

7. Report Segmentation Breakup by Application: Oncological Disorders Rare Diseases Cardiovascular Diseases Neurological Disorders Infectious Disease Others Breakup by Region: North America Asia-Pacific Europe Latin America Middle East and Africa

8. Competitive Landscape with Key Players Abeona Therapeutics Inc. Adaptimmune Therapeutics plc Adverum Biotechnologies Inc. Amgen Inc. Astellas Pharma Inc. Biogen Inc. Bluebird Bio Inc. Mustang Bio Inc. (Fortress Biotech Inc.) Novartis AG Orchard Therapeutics plc UniQure N.V. Voyager Therapeutics Inc.

9. Key Questions Answered in the Report

10. Table of Contents 1    Preface 2    Scope and Methodology     2.1    Objectives of the Study     2.2    Stakeholders     2.3    Data Sources         2.3.1    Primary Sources         2.3.2    Secondary Sources     2.4    Market Estimation         2.4.1    Bottom-Up Approach         2.4.2    Top-Down Approach     2.5    Forecasting Methodology 3    Executive Summary 4    Introduction     4.1    Overview     4.2    Key Industry Trends 5    Global Gene Therapy Market     5.1    Market Overview     5.2    Market Performance     5.3    Impact of COVID-19   5.4    Market Forecast 6     Market Breakup by Gene Type 6.1 Antigen 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Cytokine 6.2.1 Market Trends 6.2.2 Market Forecast 6.3 Tumor Suppressor 6.3.1 Market Trends 6.3.2 Market Forecast        

11. Table of Contents 6.4 Suicide Gene 6.4.1 Market Trends 6.4.2 Market Forecast 6.5 Deficiency 6.5.1 Market Trends 6.5.2 Market Forecast 6.6 Growth Factors 6.6.1 Market Trends 6.6.2 Market Forecast 6.7 Receptors 6.7.1 Market Trends 6.7.2 Market Forecast 6.8 Others 6.8.1 Market Trends 6.8.2 Market Forecast 7 Market Breakup by Vector Type 7.1 Viral Vector 7.1.1 Market Trends 7.1.2 Key Segments 7.1.2.1 Adenoviruses 7.1.2.2 Lentiviruses 7.1.2.3 Retroviruses 7.1.2.4 Adeno-Associated Virus 7.1.2.5 Herpes Simplex Virus 7.1.2.6 Poxvirus 7.1.2.7 Vaccinia Virus            7.1.2.8 Others         7.1.3 Market Forecast     7.2    Non-Viral Techniques         7.2.1 Market Trends For more information, visit : https://www.imarcgroup.com/gene-therapy-market/toc

12. Disclaimer © 2023 IMARC All Rights Reserved This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC). Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication. IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.

13. Contact Us Visit us at : https://www.imarcgroup.com TELEPHONE: [phone] E-MAIL: [email protected]